Search

Displaying results 9901 - 9910 of 10000 in total
  1. Drug

    Olaparib-bodipy FL

    go.drugbank.com/drugs/DB16263
    Investigational

    Olaparib-bodipy FL is under investigation in clinical trial NCT03085147 (A Dye for the Detection of Cancer of the Tongue and Mouth).

  2. Drug

    Pexiganan

    go.drugbank.com/drugs/DB16293
    Investigational

    Pexiganan is under investigation in clinical trial NCT01594762 (Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers).

  3. Drug

    Octovalent O-polysaccharide-toxin A conjugate vaccine

    go.drugbank.com/drugs/DB17789
    Experimental

    Octovalent O-polysaccharide-toxin A conjugate vaccine is currently being investigated to treat Pseudomonas Aeruginosa infection in patients with cystic fibrosis.[A259462]

  4. Drug

    Zaltoprofen

    go.drugbank.com/drugs/DB06737
    Investigational

    A non-steroidal anti-inflammatory drug approved for use in Japan in 1993.

  5. Drug

    Bencyclane

    go.drugbank.com/drugs/DB13488
    Experimental

    A vasodilator agent found to be effective in a variety of peripheral circulation disorders. It has various other potentially useful pharmacological effects.

    Synonyms: 3-((1-Benzylcycloheptyl)oxy)-N,N-dimethylpropylamin
  6. Drug

    RGX-501

    go.drugbank.com/drugs/DB17639
    Investigational

    It is being investigated for the treatment of homozygous familial hypercholesterolemia.[L46696] … RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells.

  7. Drug

    Ginkgolide A

    go.drugbank.com/drugs/DB06743
    ExperimentalNutraceutical

    Ginkgolide A is a highly active PAF antagonist cage molecule that is isolated from the leaves of the Ginkgo biloba tree. Shows potential in a wide variety of inflammatory and immunological disorders.

  8. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932). … The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in combination with a well-established

  9. Drug

    Froniglutide

    go.drugbank.com/drugs/DB16178
    Investigational

    Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM). … Glymera is under investigation in clinical trial NCT01658501 (Phase 2b Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of

  10. Drug

    Antipain

    go.drugbank.com/drugs/DB15251
    Experimental

    [A214484, A214487] Antipain was used in 2010 to obtain a crystal structure of the _Leishmania major_ oligopeptidase B (OPB), a serine protease that serves as a virulence factor in trypanosomatids. … [A214481] Early studies investigated the potential for antipain to alter DNA damage and chromosomal aberrations in irradiated cells or those treated with chemical mutagens such as _N_-methyl-_N_'-nitro